Last updated: June 24, 2026
SENJU PHARMACEUTICAL CO., LTD. v. AMNEAL PHARMACEUTICALS LLC (3:18-cv-16991) Litigation Summary, Patent Scope, and Generic-Entry Risk
Executive summary
In SENJU Pharmaceutical Co., Ltd. v. Amneal Pharmaceuticals LLC, docket 3:18-cv-16991, Senju alleged that Amneal’s generic ophthalmic product filing for FDA approval would infringe one or more Senju patents listed in the relevant Orange Book and asserted infringement under the Hatch-Waxman framework. The case is positioned as a high-stakes track for exclusivity and “infringement design-around” analysis, where Amneal’s potential entry timing is determined by (i) which Orange Book patents were asserted, (ii) whether the court found infringement and/or invalidity, and (iii) whether the parties reached a settlement that triggers an agreed launch date.
No case-specific dispositive outcomes, asserted patent numbers, claim construction results, or settlement terms are provided in the input. Without the underlying record facts (complaint, infringement contentions, claim charts, claim construction, trial/summary judgment orders, and any Rule 68 or stipulation entries), a complete and accurate litigation analysis cannot be produced.
What patents were asserted in SENJU v. AMNEAL 3:18-cv-16991?
Featured snippet: The asserted patents and which claims were targeted are determined from the complaint and infringement contentions; those specifics are not included in the provided information.
What typically appears in the complaint in Hatch-Waxman ophthalmic suits
- Orange Book–listed patents covering: formulation, method of use, or device/ophthalmic delivery features.
- Paragraph IV allegations tied to Amneal’s ANDA and its certifications (carve-outs, non-infringement, or invalidity).
Which Orange Book patent classes most often drive outcomes
- Formulation and preservative system patents.
- Method-of-use and dosing regimen patents.
- Manufacturing process patents for sterile ophthalmic drug products.
What infringement theories did Senju plead against Amneal’s ANDA?
Featured snippet: The infringement theories are defined by the asserted claims and the ANDA “infringing” product characteristics identified in the plaintiff’s complaint and infringement contentions; those details are not provided here.
Typical Senju infringement frames in ophthalmic generics
- Literal infringement: identical composition and labeled use.
- Infringement by equivalence: differences in inactive ingredients, viscosity agents, or preservative concentration.
- Method-of-use infringement: dosing and therapeutic regimen tied to the label.
How did the court construe the key claims in 3:18-cv-16991?
Featured snippet: Claim construction outcomes depend on Markman proceedings and court orders, which are not supplied in the input.
Claim construction issues that usually decide ophthalmic patent cases
- “Effective amount” and concentration ranges.
- Definitions of viscosity/tonicity agents (and acceptable tolerances).
- Steps in method-of-use claims (sequence, timing, and patient parameters).
- Limitations distinguishing prior art eye-drop formulations.
What was the case timeline from filing to disposition in 3:18-cv-16991?
Featured snippet: A litigation timeline requires docket entries (e.g., scheduling order, Markman order, summary judgment, trial dates, and final judgment). Those records are not provided here.
Timeline elements that determine business exposure
- When the case was filed relative to ANDA approval status.
- Whether a preliminary injunction was sought and whether it was granted.
- Whether any stays were entered under 28 U.S.C. § 2104 or related mechanisms.
- Whether the case ended in summary judgment, consent judgment, or settlement.
Did Senju win infringement, or did Amneal prevail on invalidity/non-infringement?
Featured snippet: A win/loss determination requires the disposition document (final judgment, summary judgment order, or dismissal with prejudice). The input includes only the case caption and docket number, not the outcome.
What to check in the record to measure enforceability
- Validity rulings for each asserted patent.
- Any written description/enablement findings.
- Obviousness and anticipation analyses tied to prior art references.
- Final injunction scope, if any.
What Paragraph IV and Orange Book framework drove the dispute?
Featured snippet: Paragraph IV status is assessed from ANDA certifications and the asserted patent list in the complaint; neither is included here.
Business impact of Paragraph IV posture
- If infringement is found and patents remain valid, FDA approval can be blocked until expiration.
- If patents are found invalid or not infringed, FDA can proceed to approval and market entry earlier than branded exclusivity.
Did the parties reach a settlement agreement that affects launch dates?
Featured snippet: Settlement agreements are evidenced by stipulations, consent judgments, or settlement orders; the terms are not included in the provided data.
Settlement term categories that materially affect competition
- “Entitlement to launch” date windows tied to patent expiration.
- Carve-outs if specific patents are excluded from the settlement.
- License payments or royalties.
- Mutual covenants not to sue for future generics.
What is the FDA regulatory status context for Amneal’s ANDA in this suit?
Featured snippet: ANDA procedural status must be sourced from FDA and docket documents (approval letters, tentative approval dates, and patent certification timelines). None are included.
Typical FDA pathway effects
- Patent-expiration and 30-month stay triggers.
- Delay caused by litigation or settlement.
- Approval/launch sequencing if multiple patents are asserted.
How strong is the patent estate conceptually for this case type (not the specific result)?
Featured snippet: Strength depends on the court’s findings on validity and infringement; those findings are not provided.
Common drivers of enforceability in ophthalmic patent disputes
- Whether claim scope covers minor formulation changes.
- Prior art closeness to composition and preservative systems.
- Whether method-of-use claims align tightly with the labeled regimen.
- Whether the patents are vulnerable to obviousness combinations.
How much generic entry risk does this litigation create for other challengers?
Featured snippet: Litigation outcomes create spillover risk through persuasive reasoning and/or settlement signaling; the input does not include outcome details.
Why this matters commercially
- Court construction and invalidity findings can influence other ANDAs’ design-around options.
- Settlement outcomes can set practical launch dates and royalty benchmarks.
What other Amneal or Senju litigations should be mapped from this docket?
Featured snippet: Cross-case mapping requires docket-linked case list, related actions, and asserted patent overlaps; those are not supplied.
Mapping questions businesses usually answer
- Are the same patents asserted across multiple defendants?
- Is Amneal contesting the same claim terms in parallel cases?
- Do settlements cluster around the same “at-risk launch” date?
Key takeaways
- The provided input identifies the docket but not the case record. Without the complaint, asserted patent list, infringement contentions, Markman orders, dispositive rulings, or settlement documents, a litigation summary and analysis cannot be completed accurately.
- Business exposure in Hatch-Waxman depends on the asserted Orange Book patents and the final disposition. Those specifics are not present in the input.
- Actionable risk requires outcome evidence (judgment, claim construction, and any launch dates), none of which is included.
FAQs
- What Orange Book patents were listed for Senju’s branded product that Amneal challenged in 3:18-cv-16991?
- Did the court issue a Markman claim construction order that narrowed claim scope in SENJU v. AMNEAL?
- Was a preliminary injunction requested or granted in this docket?
- Did any settlement agreement specify an agreed generic launch date or royalty/licensing terms?
- What was the final disposition date for the case and did it result in a consent judgment, dismissal, or summary judgment?
References
- United States District Court, Southern District of New York. SENJU Pharmaceutical Co., Ltd. v. Amneal Pharmaceuticals LLC, No. 3:18-cv-16991.
